Cargando…
Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
SIMPLE SUMMARY: A phase 3 IMbrave150 trial showed that atezolizumab plus bevacizumab combination therapy had an improved survival benefit over sorafenib. An excellent direct anti-cancer effect, including progression-free survival and objective response rate, was also observed with this combination t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582435/ https://www.ncbi.nlm.nih.gov/pubmed/34771637 http://dx.doi.org/10.3390/cancers13215475 |